About the Company
Established in 2011, OncoSec Medical Incorporated is a San Diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. Through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients.
OncoSec’s investigational platform, ImmunoPulse®, is designed to enhance local delivery and uptake of DNA-based therapeutics directly into tumors. Clinical studies of ImmunoPulse® with DNA-based IL-12 demonstrated a local immune response, and subsequently, a systemic effect. We are currently conducting pre-clinical and clinical studies targeting various cancers in collaboration with several prominent academic medical centers and companies.
To date, study results have laid the groundwork for OncoSec’s expansion into new DNA-encoded therapeutic candidates and tumor indications. Data also indicates this platform shows clinical activity as a monotherapy and promise as a combination approach.
OncoSec Presents Positive Phase 2 Data for ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non-Responder Melanoma Patients
Data from Recently Completed Phase 2 Monotherapy and Combination Therapy Studies Presented at the 2017 9th World Congress of Melanoma – A Joint Meeting with the Society for Melanoma Research 8 of 21 (38.1%) Achieved RECIST v1.1 Durable Complete...
OncoSec Announces Acceptance of Late Breaking Abstract at Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017
Additional abstract highlighting preclinical data from OncoSec’s novel multi-gene expression platform SAN DIEGO, Oct. 11, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present updated clinical data from its phase 2 Investigator Sponsored...
OncoSec to Present Updated Clinical and Immune Biomarker Data from its Monotherapy and Combination Therapy Studies with ImmunoPulse® IL-12 at the 9th World Congress of Melanoma – A Joint Meeting with the Society for Melanoma Research
OncoSec presented at the 2nd Annual Biomarkers & Precision Medicine USA Congress SAN DIEGO, Oct. 12, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present new clinical data on ImmunoPulse® IL-12 (intratumoral pIL-12...
OncoSec Initiates Registration Directed Clinical Trial, KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Merck’s KEYTRUDA® (pembrolizumab)
Enrolling patients with unresectable metastatic melanoma who have progressed or are progressing on an anti-PD-1 therapy Global study in the U.S. and Australia ImmunoPulse® IL-12 granted Fast Track and Orphan Drug Designation in the U.S. SAN DIEGO, Oct. 10, 2017 /PRNewswire/...